BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 38226313)

  • 1. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis.
    Chen S; Huang M; Zhang L; Huang Q; Wang Y; Liang Y
    Comput Struct Biotechnol J; 2024 Dec; 23():369-383. PubMed ID: 38226313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tumor-associated endothelial signature score model in immunotherapy and prognosis across pan-cancers.
    Chen S; Zhang L; Huang M; Liang Y; Wang Y
    Front Pharmacol; 2023; 14():1190660. PubMed ID: 37719845
    [No Abstract]   [Full Text] [Related]  

  • 3. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
    Tian M; Yang J; Han J; He J; Liao W
    Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
    Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
    Altern Ther Health Med; 2024 Mar; ():. PubMed ID: 38518167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
    Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
    Front Genet; 2022; 13():1017866. PubMed ID: 36699466
    [No Abstract]   [Full Text] [Related]  

  • 8. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
    Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 10. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
    Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
    Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy.
    Yao Y; Wang J; Yang F; Gao W
    Front Immunol; 2022; 13():924498. PubMed ID: 35844536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Infiltrating PD-1
    Yang Z; Deng Y; Cheng J; Wei S; Luo H; Liu L
    Front Oncol; 2021; 11():695006. PubMed ID: 34604032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
    Ma P; Sun W
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granzymes expression patterns predict immunotherapy response and identify the heterogeneity of CD8+ T cell subsets.
    Li J; Zhang H; Wu J; Li L; Xu B; Song Q
    Cancer Biomark; 2023; 38(1):77-102. PubMed ID: 37545222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel pyroptosis-regulated gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.
    Zhang B; Wang Z
    Front Mol Biosci; 2022; 9():890215. PubMed ID: 36262473
    [No Abstract]   [Full Text] [Related]  

  • 18. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
    Song J; Yang R; Wei R; Du Y; He P; Liu X
    Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
    Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
    Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analyses of a CD8
    Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
    BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.